[1] |
Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias[J]. J Am Acad Dermatol, 2005,53(1):1⁃37; quiz 38⁃40. doi: 10.1016/j.jaad.2004.06.015.
|
[2] |
Sundberg JP, Hordinsky MK, Bergfeld W, et al. Cicatricial alopecia research foundation meeting, May 2016: progress towards the diagnosis, treatment and cure of primary cicatricial alopecias[J]. Exp Dermatol, 2018,27(3):302⁃310. doi: 10.1111/exd.13495.
|
[3] |
Hordinsky M. Scarring alopecia: diagnosis and new treatment options[J]. Dermatol Clin, 2021,39(3):383⁃388. doi: 10.1016/j.det.2021.05.001.
|
[4] |
Joshi TP, Zhu H, Naqvi Z, et al. Prevalence of lichen planopilaris in the United States: a cross⁃sectional study of the All of Us research program[J]. JAAD Int, 2022,8:69⁃70. doi: 10.1016/j.jdin.2022.05.003.
|
[5] |
Porriño⁃Bustamante ML, Fernández⁃Pugnaire MA, Arias⁃Santiago S. Frontal fibrosing alopecia: a review[J]. J Clin Med, 2021,10(9):1805. doi: 10.3390/jcm10091805.
|
[6] |
Hajizadeh N, Heidari A, Sadeghi S, et al. Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: a systematic review[J]. PLoS One, 2024,19(2):e0293433. doi: 10.1371/journal.pone.0293433.
|
[7] |
Tavakolpour S, Mahmoudi H, Abedini R, et al. Frontal fibrosing alopecia: an update on the hypothesis of pathogenesis and treatment[J]. Int J Womens Dermatol, 2019,5(2):116⁃123. doi: 10.1016/j.ijwd.2018.11.003.
|
[8] |
Tziotzios C, Petridis C, Dand N, et al. Genome⁃wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA⁃B*07:02[J]. Nat Commun, 2019,10(1):1150. doi: 10.1038/s41467⁃019⁃09117⁃w.
|
[9] |
Miao YJ, Jing J, Du XF, et al. Frontal fibrosing alopecia: a review of disease pathogenesis[J]. Front Med (Lausanne), 2022,9:911944. doi: 10.3389/fmed.2022.911944.
|
[10] |
Prasad S, Marks DH, Burns LJ, et al. Patch testing and contact allergen avoidance in patients with lichen planopilaris and/or frontal fibrosing alopecia: a cohort study[J]. J Am Acad Dermatol, 2020,83(2):659⁃661. doi: 10.1016/j.jaad.2020.01.026.
|
[11] |
Dubin C, Glickman JW, Del Duca E, et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement[J]. J Am Acad Dermatol, 2022,86(3):551⁃562. doi: 10.1016/j.jaad.2021. 05.016.
|
[12] |
Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: a case series[J]. Dermatol Ther, 2018,31(6):e12656. doi: 10.1111/dth.12656.
|
[13] |
Fechine C, Valente N, Romiti R. Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features[J]. An Bras Dermatol, 2022,97(3):348⁃357. doi: 10.1016/j.abd.2021.08.008.
|
[14] |
Dunn C, Griffith V, Coican A, et al. Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: a case series and review of the literature[J]. JAAD Case Rep, 2023,40:47⁃52. doi: 10.1016/j.jdcr.2023.07.037.
|
[15] |
Moussa A, Bhoyrul B, Asfour L, et al. Treatment of lichen planopilaris with baricitinib: a retrospective study[J]. J Am Acad Dermatol, 2022,87(3):663⁃666. doi: 10.1016/j.jaad.2022. 02.027.
|
[16] |
Plante J, Eason C, Snyder A, et al. Tofacitinib in the treatment of lichen planopilaris: a retrospective review[J]. J Am Acad Dermatol, 2020,83(5):1487⁃1489. doi: 10.1016/j.jaad.2020.05. 104.
|
[17] |
Rácz E, Gho C, Moorman PW, et al. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review[J]. J Eur Acad Dermatol Venereol, 2013,27(12):1461⁃1470. doi: 10.1111/jdv.12139.
|
[18] |
Holmes S, Ryan T, Young D, et al. Frontal Fibrosing Alopecia Severity Index (FFASI): a validated scoring system for assessing frontal fibrosing alopecia[J]. Br J Dermatol, 2016,175(1):203⁃207. doi: 10.1111/bjd.14445.
|
[19] |
Vañó⁃Galván S, Molina⁃Ruiz AM, Serrano⁃Falcón C, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients[J]. J Am Acad Dermatol, 2014,70(4):670⁃678. doi: 10.1016/j.jaad.2013.12.003.
|
[20] |
Price VH. The medical treatment of cicatricial alopecia[J]. Semin Cutan Med Surg, 2006,25(1):56⁃59. doi: 10.1016/j.sder.2006.01.008.
|
[21] |
Mahmoudi H, Rostami A, Tavakolpour S, et al. Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial[J]. J Dermatolog Treat, 2022,33(1):284⁃290. doi: 10.1080/09546634.2020.1750553.
|
[22] |
Imhof R, Tolkachjov SN. Optimal management of frontal fibrosing alopecia: a practical guide[J]. Clin Cosmet Investig Dermatol, 2020,13:897⁃910. doi: 10.2147/CCID.S235980.
|
[23] |
Pindado⁃Ortega C, Pirmez R, Melo DF, et al. Low⁃dose oral minoxidil for frontal fibrosing alopecia: a 122⁃patient case series[J]. Actas Dermosifiliogr, 2025,116(4):T407⁃T411. doi: 10. 1016/j.ad.2025.02.008.
|
[24] |
Ly N, McClure EM, Hordinsky MK, et al. Safety and efficacy of minoxidil treatment in scarring alopecia: a scoping review[J]. J Drugs Dermatol, 2024,23(3):146⁃151. doi: 10.36849/jdd.7743.
|
[25] |
Chen LC, Ogbutor C, Kelley KJ, et al. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia[J]. J Am Acad Dermatol, 2024,90(6):1260⁃1262. doi: 10.1016/j.jaad.2024.01.060.
|
[26] |
Williams KN, Perez SM, Burroway B, et al. Topical ruxolitinib in the management of frontal fibrosing alopecia and/or lichen planopilaris: a single⁃center retrospective cohort study[J]. J Am Acad Dermatol, 2025,92(1):170⁃172. doi: 10.1016/j.jaad.2024. 09.032.
|
[27] |
Chiang C, Sah D, Cho BK, et al. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system[J]. J Am Acad Dermatol, 2010,62(3):387⁃392. doi: 10.1016/j.jaad.2009.08.054.
|
[28] |
Strazzulla LC, Avila L, Li X, et al. Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: a retrospective review of 92 cases[J]. J Am Acad Dermatol, 2018,78(1):203⁃205. doi: 10.1016/j.jaad.2017.07.035.
|
[29] |
Mesinkovska NA, Tellez A, Dawes D, et al. The use of oral pioglitazone in the treatment of lichen planopilaris[J]. J Am Acad Dermatol, 2015,72(2):355⁃356. doi: 10.1016/j.jaad.2014. 10.036.
|
[30] |
Peterson EL, Gutierrez D, Brinster NK, et al. Response of lichen planopilaris to pioglitazone hydrochloride[J]. J Drugs Dermatol, 2019,18(12):1276⁃1279.
|
[31] |
Seo HM, Oh SU, Kim S, et al. Dutasteride in the treatment of frontal fibrosing alopecia: systematic review and meta⁃analysis[J]. J Eur Acad Dermatol Venereol, 2024,38(8):1514⁃1521. doi: 10.1111/jdv.19802.
|
[32] |
Vano⁃Galvan S, Saceda⁃Corralo D. Oral dutasteride is a first⁃line treatment for frontal fibrosing alopecia[J]. J Eur Acad Dermatol Venereol, 2024,38(8):1455⁃1456. doi: 10.1111/jdv.20174.
|
[33] |
Fatemi F, Mohaghegh F, Danesh F, et al. Isotretinoin for the treatment of facial lichen planopilaris: a new indication for an old drug, a case series study[J]. Clin Case Rep, 2020,8(12):2524⁃2529. doi: 10.1002/ccr3.3210.
|
[34] |
Cranwell WC, Sinclair R. Familial frontal fibrosing alopecia treated with dutasteride, minoxidil and artificial hair transplantation[J]. Australas J Dermatol, 2017,58(3):e94⁃e96. doi: 10.1111/ajd.12499.
|
[35] |
Vañó⁃Galván S, Villodres E, Pigem R, et al. Hair transplant in frontal fibrosing alopecia: a multicenter review of 51 patients[J]. J Am Acad Dermatol, 2019,81(3):865⁃866. doi: 10.1016/j.jaad.2019.05.031.
|
[36] |
Pathoulas JT, Flanagan KE, Su MY, et al. A prospective pilot study of narrowband UV⁃B treatment of lichen planopilaris[J]. J Am Acad Dermatol, 2022,87(3):703⁃705. doi: 10.1016/j.jaad. 2022.04.054.
|
[37] |
Subash J, Eginli A, Bomar L, et al. Frontal fibrosing alopecia treatment with Nd:YAG (1064 nm) nonablative laser[J]. Int J Womens Dermatol, 2021,7(3):355⁃356. doi: 10.1016/j.ijwd. 2020.10.007.
|
[38] |
Navarini AA, Kolios AG, Prinz⁃Vavricka BM, et al. Low⁃dose excimer 308⁃nm laser for treatment of lichen planopilaris[J]. Arch Dermatol, 2011,147(11):1325⁃1326. doi: 10.1001/archdermatol.2011.335.
|
[39] |
Vañó⁃Galván S, Trindade de Carvalho L, Saceda⁃Corralo D, et al. Oral minoxidil improves background hair thickness in lichen planopilaris[J]. J Am Acad Dermatol, 2021,84(6):1684⁃1686. doi: 10.1016/j.jaad.2020.04.026.
|